homologous use

Take-homes from new FDA NEJM stem cell piece including surprises

Peter-Marks-Scott-Gottlieb-FDA

FDA Commissioner Scott Gottlieb and CBER Director, Peter Marks, have just published a new piece on stem cells and regenerative medicine in the New England Journal of Medicine (NEJM). What are the core points here and what can we learn from reading between the lines a bit? There are some expected things and then some …

Take-homes from new FDA NEJM stem cell piece including surprises Read More »

Fat stem cells are drugs & more: FDA final guidances point to a new era

FDA-stem-cell-policy-flow-chart-e1510854295902

Are fat stem cells a drug? Today the FDA definitively indicated “yes” without leaving much of any room for exceptions on this question. This morning the FDA made a major announcement on stem cell policy regarding its current thinking on oversight of regenerative medicine and issued four guidances, including two each in final and in …

Fat stem cells are drugs & more: FDA final guidances point to a new era Read More »

Stem cell myth: they are homologous to everything

spackle-stem-cells-e1472152006313

Some stem cell clinics sometimes use questionable ideas to bypass FDA regulations and I’d go far as to say some of these are outright stem cell myths. One such argument that seems like a myth in my opinion relates to the idea of “homologous use”, which is one of the hottest issues in stem cells in the clinical arena right …

Stem cell myth: they are homologous to everything Read More »

New FDA Interview on April stem cell meeting & draft guidances

FDA-draft-guidance

Below is a my interview with an FDA spokesperson on the upcoming April public meeting on the four recent draft guidances related to the regulation of HCT/Ps, including stem cell treatments. This meeting and the draft guidances could have substantial impact on future regulatory frameworks for stem cell treatments so I thought it important to …

New FDA Interview on April stem cell meeting & draft guidances Read More »

More tough FDA draft guidance on stem cells…still no action

FDAADF-300x252

The FDA released more draft guidance with strong relevance to the stem cell field. This October 2015 new draft guidance follows about a year after three other previous draft guidances that made it clear the current FDA thinking on various issues including stromal vascular fraction (SVF; fat stem cells) was much more restrictive than generally …

More tough FDA draft guidance on stem cells…still no action Read More »

Stem cell clinics, FDA, & giant, unapproved for-profit human experiments

Stem-cell-facelift-comic-e1452454386279

When I started blogging in 2010 the stem cell arena was a very different place including the fact I could count the number of US stem cell clinics on one hand. This blog, called The Niche for many years, was just “Knoepfler Stem Cell Blog” back then. Also, back then the hot topic was the …

Stem cell clinics, FDA, & giant, unapproved for-profit human experiments Read More »

FDA to Put Mushrooming Fat Stem Cell Clinics on Crash Diet?

Stembucks

Is it the beginning of the end for dubious American clinics that sell transplants of unproven and non-FDA approved fat stem cell injections? As the year of 2014 was winding down, the FDA issued two key new draft guidances (see here and here) that could prove to be crash diets for these burgeoning fat stem cell clinics. (Update: As of …

FDA to Put Mushrooming Fat Stem Cell Clinics on Crash Diet? Read More »

New Interview with FDA on Key Stem Cell Regulatory Issues & Its Own Research

FDA3

It’s been a seemingly rather quiet year on the regulatory front in the US when it comes to direct-to-consumer stem cell interventions even as the number of dubious stem cell clinics continues to skyrocket. I requested an interview with the FDA to cover the key pressing issues in this arena. I want to thank the …

New Interview with FDA on Key Stem Cell Regulatory Issues & Its Own Research Read More »

Time to bone up on homologous use in the stem cell field

What does homologous use mean? Navigating the arena of clinical use of a biologic such as stem cells or differentiated cells made from stem cells can be challenging. There are many important issues including what defines “minimal manipulation” of biologics such as cells. One particular issue that is critically important and has drawn less attention …

Time to bone up on homologous use in the stem cell field Read More »